STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

LogicMark, Inc. Announces Closing of $14.4 Million Public Offering

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

LogicMark (NASDAQ: LGMK) has closed a public offering raising $14.4 million in gross proceeds. The offering consisted of 2,260,000 units and 22,146,750 pre-funded units, priced at $0.59 and $0.589 per unit respectively. Each unit includes one share of common stock (or pre-funded warrant), plus Series C and Series D warrants.

The Series C warrants are exercisable at $0.59 per share with a 5-year term, while Series D warrants are exercisable at $0.885 per share with a 2.5-year term. Both warrant series require stockholder approval and possible charter amendments before exercise. The company plans to use the proceeds for sales and marketing of products, working capital, and general corporate purposes.

Loading...
Loading translation...

Positive

  • Secured $14.4 million in gross proceeds from public offering
  • Warrants provide potential for additional future capital through exercise

Negative

  • Significant dilution through issuance of over 24.4 million units
  • Warrant exercise requires stockholder approval and possible charter amendments
  • Low unit pricing at $0.59 indicates potential financial distress

News Market Reaction 1 Alert

-7.70% News Effect

On the day this news was published, LGMK declined 7.70%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

LOUISVILLE, Ky., Feb. 18, 2025 (GLOBE NEWSWIRE) -- LogicMark, Inc. (NASDAQ: LGMK) (the “Company”), a provider of personal emergency response systems, health communications devices, and technology for the growing care economy, today announced the closing of its public offering.

The public offering consisted of 2,260,000 units and 22,146,750 pre-funded units, with each unit consisting of one share of common stock (or for each pre-funded unit, one pre-funded warrant in lieu of one share of common stock), one Series C warrant to purchase one share of common stock and one Series D warrant to purchase one share of common stock. Gross proceeds, before deducting placement agent fees and estimated offering expenses, were approximately $14.4 million. The Company currently intends to use the net proceeds from the offering for sales and marketing support of its legacy and new products, working capital and general corporate purposes.

Each unit was sold at a public offering price of $0.59 per unit (or $0.589 per pre-funded unit). Each of the Series C warrants and Series D warrants are only exercisable upon receipt of stockholder approval and, if applicable, upon effectiveness of a charter amendment effecting a reverse stock split or increasing the Company’s number of authorized shares of capital stock. Each of the Series C warrants are exercisable at a price of $0.59 per share and each of the Series D warrants are exercisable at a price of $0.885 per share, with the Series C warrants expiring 5 years from the date of their issuance and the Series D warrants expiring 2.5 years from the date of their issuance. The shares of common stock (or pre-funded warrants included in the pre-funded units) and accompanying Series C warrants and Series D warrants included in the units and in the pre-funded units were purchased together in the offering but were issued separately and were immediately separable upon issuance.

The offering was conducted pursuant to the Company's registration statement on Form S-1, as amended (File No. 333-284135), which was declared effective by the U.S. Securities and Exchange Commission (“SEC”), on February 14, 2025 and the Registration Statement on Form S-1MEF (File No. 333-284997) filed by the Company with the SEC on February 14, 2025 pursuant to Rule 462(b) of the Securities Act of 1933, as amended. A final prospectus relating to the offering was filed with the SEC on February 18, 2025 and is available on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus relating to the offering may also be obtained by contacting Roth Capital Partners, LLC at 888 San Clemente Drive, Newport Beach CA 92660, by phone at (800) 678-9147.

Roth Capital Partners acted as exclusive placement agent and Sullivan & Worcester LLP served as special counsel for the Company in connection with the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

All press releases, SEC filings, and webcast replays are accessible on the LogicMark, Inc. investor relations website

About Us   
LogicMark, Inc. (Nasdaq: LGMK) is on a mission to let people of all ages lead a life with dignity, independence, and the joy of possibility. The Company provides personal safety and emergency response systems, health communications devices, personal safety apps, services, and technologies to create a Connected Care Platform. Made up of a team of leading technologists with a deep understanding of IoT, AI, and machine learning and a passionate focus on understanding consumer needs, LogicMark is dedicated to building a ‘’Care Village’’ with proprietary technology and creating innovative solutions for the care economy. The Company’s PERS technologies are sold through the United States Veterans Health Administration, dealers, distributors, and direct-to-consumer. LogicMark has been awarded a contract by the U.S. General Services Administration that enables the Company to distribute its products to federal, state, and local governments. For more information visit LogicMark.com.

Cautionary Statement Regarding Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to, among other things, the anticipated use of proceeds from such offering, and the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company’s ability to implement its long-range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; the Company’s ability to maintain its Nasdaq listing for its common stock; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the SEC. Should one or more of these risks or uncertainties materialize, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this press release as intended, planned, anticipated, believed, estimated or expected. Any forward-looking statement made by us in this press release is based on information currently available to us and speaks only as of the date on which it is made. Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

Investor Relations Contact 
investors@logicmark.com


FAQ

How much did LogicMark (LGMK) raise in its February 2025 public offering?

LogicMark raised $14.4 million in gross proceeds through its February 2025 public offering.

What is the exercise price of LGMK's Series C and Series D warrants?

Series C warrants are exercisable at $0.59 per share, while Series D warrants are exercisable at $0.885 per share.

How many units were sold in LGMK's February 2025 public offering?

The offering included 2,260,000 regular units and 22,146,750 pre-funded units.

What are the expiration terms for LGMK's Series C and D warrants?

Series C warrants expire 5 years from issuance, while Series D warrants expire 2.5 years from issuance.

How does LogicMark plan to use the proceeds from its 2025 public offering?

LogicMark plans to use the proceeds for sales and marketing support of products, working capital, and general corporate purposes.
LOGICMARK INC

OTC:LGMK

LGMK Rankings

LGMK Latest News

LGMK Latest SEC Filings

LGMK Stock Data

6.63M
807.29k
0.88%
0.13%
0.6%
Health Information Services
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
LOUISVILLE